Essais liés9clinical trials
VilleBox Hilllocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07282574

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
JNJ-63733657 Alzheimer Phase 2 NCT04619420 Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease TERMINATED
Nivolumab Cancer Phase 3 NCT06561386 RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% RECRUITING
Rituximab SEP Phase 3 NCT00004179 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma COMPLETED
Retatrutide Maladie rénale chronique Phase 3 NCT06383390 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) ACTIVE_NOT_RECRUITING
RO7268489 SEP Phase 2 NCT07282574 Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RECRUITING
BMS-986368 Myopathies Phase 2 NCT06782490 MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity RECRUITING
Trontinemab Alzheimer Phase 3 NCT07170150 TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease ACTIVE_NOT_RECRUITING
Efgartigimod PH20 SC Myasthénie Phase 3 NCT06558279 ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04544449 FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING